ClinicalTrials.gg
RecruitingNCT06787144CMLUpdated Jul 1, 2025

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

A Phase 1 interventional study of ELVN-001 in CML (Chronic Myelogenous Leukemia) and Chronic Phase CML, sponsored by Enliven Therapeutics. Recruiting at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Enliven Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan — 5 open to participants now, 7 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan.

Planned enrollment
26th of 29
21 · median 59
Started
2025
the only one that year
Phase 1
3 of 32
1 open now
Registered
31st of 32
by date
Lead sponsor
1 of 32
Enliven Therapeutics

Among the 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan, this one is the 26th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 31st registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

5 of the 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.

Read the detailed description

This first-in-human trial with ELVN-001 is a dose escalation study with the primary purpose to identify the recommended dose(s) for expansion (RDEs) of single agent ELVN-001 in chronic phase CML with or without T315I mutations. The safety, tolerability and pharmacokinetic profile of ELVN-001 will be assessed together with an evaluation of changes in BCR-ABL1 transcript. An understanding of the safety profile, PK and preliminary evidence of anti-CML activity will be used to inform future development of ELVN-001 in adults with CML. By virtue of its predicted pharmacological profile ELVN-001 has the potential to be tolerable and achieve a deep molecular response in patients with CML with or without T315I mutations who have failed, or are intolerant to, or not a candidate for, at least 2 prior TKIs.

03

Conditions studied

  • CML (Chronic Myelogenous Leukemia)
  • Chronic Phase CML

Keywords

  • CML
  • Tyrosine Kinase Inhibitor
  • T315I
  • T315I Mutant
  • BCR-ABL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BCR::ABL1 positive CP-CML that has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.
  • performance status of 0 to 2.
  • The patient was born in Japan and both parents and grandparents are Japanese.
  • Adequate hematologic, hepatic and renal function.
  • Prior bone marrow transplant allowed if ≥ 6 months prior to the first dose of ELVN-001.

Exclusion criteria

Exclusion Criteria:

  • Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, whichever is longer.
  • History of acute tyrosine kinase inhibitor (TKI)-related pancreatitis within 6 months of study entry. Active chronic pancreatitis, or pancreatic disease due to any cause.
  • >470 ms.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation

    ELVN-001 administered in 3+3 dose escalation

    Drug: ELVN-001

  • Experimental
    Part 2 Dose Exploration

    ELVN-001 administered to approximately 6 participants per dose level who may be enrolled at or below the dose levels that have been deemed safe and tolerable in Part 1

    Drug: ELVN-001

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of dose limiting toxicities

    DLTs will be used to support that the recommended doses for expansion are \</= MTD

    Time frame: 28 days

  2. Part 1: Incidence of adverse events (AEs)

    Adverse events will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: Up to 28 days

  3. Part 1: Incidence of clinically significant laboratory abnormalities

    Clinically significant laboratory abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: Up to 28 days

  4. Part 1: Incidence of clinically significant ECG abnormalities

    Clinically significant ECG abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: Up to 28 days

  5. Part 2: Incidence of adverse events

    Adverse events will be used to support that the dose(s) evaluated in exploration is tolerable

    Time frame: Up to 3 years

  6. Part 2: Incidence of clinically significant laboratory abnormalities

    Clinically significant ECG abnormalities will be used to support that the dose(s) evaluated in exploration is tolerable

    Time frame: Up to 3 years

  7. Part 2: Incidence of clinically significant ECG abnormalities

    Clinically significant ECG abnormalities will be used to support that the recommended dose(s) evaluated in exploration is tolerable

    Time frame: Up to 3 years

Secondary outcomes

  1. Area under the curve

    PK parameter based on measurement of drug concentration in blood over time

    Time frame: 6 months

  2. Maximum concentration

    PK parameter based on measurement of drug concentration in blood

    Time frame: 6 months

  3. Time of maximum concentration

    PK parameter which is the time at which the highest concentration of drug in the blood is measured

    Time frame: 6 months

  4. Minimum concentration

    PK parameter based on the measurement of the drug concentration that is at the lowest level once steady state has been achieved.

    Time frame: 6 months

  5. Molecular response (MR)

    Measured by quantitative polymerase chain reaction of BCR-ABL transcript levels

    Time frame: Up to 3 years

  6. Duration of Molecular Response

    Time from first molecular response (as measured by quantitative polymerase chain reaction of BCR-ABL transcript levels) to loss of response or discontinuation of study drug

    Time frame: Up to 3 years

  7. Complete Hematologic Response (CHR)

    The proportion of patients who achieve a CHR who are not in CHR at baseline

    Time frame: Up to 3 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 36 months after the start.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Jan 22, 2025
StartActual
Jan 23, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06787144
Lead sponsor
Enliven Therapeutics
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Jan 23, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 1, 2025

Study contacts

Yuzo Tomonaga
Contact
ClinicalTrialInformation@cmic.co.jp
+81-3-6779-8000
Helen Collins, MD
study director · Enliven Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relcobatinib

Start the discussion